Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 756 participants.
Also called NCT03855826
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 756 participants
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Registry
-
NCT03855826
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT03855826. Randomized; no masking; primary purpose treatment. Start 2019-01-15 (actual); primary completion 2020-01-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.
- Condition
- Ventricular Tachycardia
- Condition
- Ventricular Fibrillation
- Intervention (Drug)
- Nifekalant hydrochloride
- Intervention (Drug)
- Amiodarone
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct03855826- Content hash
39dcfee208d7304e23af5bcba178e7bfc26f5d680541341563c4140e6adeb5d1